Scroll for more
news Aug 31, 2016

Leading British technology company rebrands to better reflect power and breadth of technology

BenevolentAI, a leading British artificial intelligence (“AI”) company that specializes in applying AI to advance scientific discovery, today announced that one of its companies – Stratified Medical, has changed its name to ‘BenevolentBio’.

Founded in 2013, BenevolentAI is leading the way in harnessing and applying the power of AI to turn the world’s highly fragmented scientific research data into new insight and usable knowledge.  By doing so, BenevolentAI is using AI as a ‘force for good’ by combining AI and other technologies with biology, chemistry and pharmaceutical know-how to discover, develop and accelerate better treatments as well as potential cures for diseases.

The proprietary AI and machine learning technology developed at BenevolentAI has already yielded an active drug portfolio that currently includes over a dozen drug development programs across four distinct disease areas ranging from neurodegenerative disorders to rare cancers.

However, as part of its longer term strategy, BenevolentAI is looking to broaden the application of its technology to sectors outside of human healthcare and drug discovery.  The company has therefore organised itself into two wholly owned, integrated and complementary subsidiaries:

Ken Mulvany, Chairman of BenevolentAI commented:

“We want to send a clear message to people that we are a technology company which is using AI not only for good, but in order to solve some of the world’s great challenges.  We’ve already started to harness AI to accelerate the speed at which new drugs can be developed for some of humanity's most debilitating diseases – however our ambition as a technology company doesn’t stop there.

Having the ability to turn the world’s mass of highly fragmented scientific information into new and ultimately useable knowledge means that there is huge potential to revolutionise other industries too. The way we’ve brought AI technology and bioscience together is certainly unique and something we want to replicate in other industries over the longer term.”